Prevalence of adult AD ranged from 2.1% to 4.9% across countries. Severe AD represented a small proportion of the overall AD population regardless of measure or region.

Background: Little is known on the current global prevalence of atopic dermatitis (AD) in the pediatric population.Objective: To estimate the real-world global prevalence of AD in the pediatric population and by disease severity. Methods: This international, cross-sectional, web-based survey of children and adolescents (6 months to <18 years old) was conducted in the following 18 countries:

Background Cross-sectional data on patient burden in adults with atopic dermatitis (AD) from real-world clinical practice are limited.Objective This study compared patient-reported burden associated with adult AD across severity levels from clinical practices in Canada and Europe.Methods This study included adults (18-65 years) diagnosed with AD by dermatologists, general practitioners or allergists. Participants categorized as mild (n = 547; 37.3%), moderate (n = 520; 35.4%) or severe (n = 400; 27.3%) based on Investigator's Global Assessment completed a questionnaire that included pruritus and pain numerical rating scales, Patient-Oriented-Scoring of Atopic Dermatitis (PO-SCORAD) itch and sleep visual analogue scales, Dermatology LifeQuality Index (DLQI), and the Hospital Anxiety and Depression Scale (HADS). Participants were also stratified by inadequate efficacy/intolerance/contraindication to cyclosporine [Cyclo; n = 62 (4 mild, 18 moderate, 40 severe)] and any systemic immunomodulatory agent [IMM; n = 104 (13 mild, 31 moderate, 60 severe)] and compared with the severe group excluding participants identified as Cyclo/IMM. ResultsAge was similar across severity groups; the proportion of women was higher in the mild group relative to severe (61.2% vs. 50.5%; P < 0.001). Compared with moderate and mild, participants with severe AD had more comorbidities, higher itch and pain severity, worse sleep and higher levels of anxiety and depression (all P < 0.001). Mean AE SD DLQI score among participants with severe AD (16.2 AE 6.9) showed a large effect on quality of life that was higher than those with moderate (10.2 AE 6.3) and mild (5.5 AE 4.9) (both P < 0.001). The burden among Cyclo and IMM subgroups was generally similar to that of participants with severe AD.Conclusions Adults with AD reported a substantial burden across multiple domains that was significantly higher in those with severe disease. The burden among participants in the Cyclo/IMM subgroups was similar to those with severe AD.

Background: The diagnostic processes for chronic abdominal conditions are challenging. Despite their tendency for diagnostic tests in patients with irritable bowel syndrome (IBS) symptoms, clinicians are encouraged to make a positive diagnosis based on symptom criteria without alarm signs. We explored how European physicians diagnose and manage patients suffering from IBS. Methods: We conducted a vignette-based survey to evaluate the diagnostic approaches in four standardized patients with IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), inflammatory bowel disease (IBD) and chronic constipation (CC). General practitioners (GP, n ¼ 104), gastroenterologists (GE, n ¼ 100) and IBS experts (n ¼ 25) from five European countries participated. Results: Experts showed the highest rates of correct diagnoses (88%-92%) for all cases except CC (only 60%) and were more prone to a positive diagnosis (64%/68% in IBS-C/CC), whereas GEs and GPs tended toward a diagnosis by exclusion (63%/ 63% and 62%/60% in IBS-C/CC). In the CC vignette, conducting tests was more frequent than prescribing treatment among 44% experts, 63% GEs and 36% GPs. The diagnosis of IBD presented little difficulty for any of the participants. Conclusions: This study highlights the difficulties in confidently diagnosing chronic functional bowel conditions, especially for non-experts, whereas IBD caused little difficulty. Differentiating between IBS-C and CC seemed particularly challenging, even for experts.

A807patients (n= 102), analyses were performed on itch (assessed by a 0-10 numeric rating scale [NRS] ), Psoriasis Skin Appearance Bothersomeness (PSAB, score range 0-30), and HRQoL (assessed by the Dermatology Life Quality Index (DLQI; score range 0−30). Treatment comparisons were made using an ANCOVA model with missing values imputed by last observation carried forward. Results: Patients treated with IXE had statistically significantly greater reductions in itch vs. ETN and PBO as early as week 1 (Q2W -3.